Skip to search formSkip to main contentSkip to account menu

ABT751

Known as: ABT-751 
An orally bioavailable antimitotic sulfonamide. ABT- 751 binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of… 
National Institutes of Health

Related topics

Related topics

4 relations
E 7010Microtubule ProcessNCIt Antineoplastic Agent Terminology

Broader (1)

Sulfonamides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Concise syntheses of 7-anilino-indoline-N-benzenesulfonamides as antimitotic and vascular disrupting agents.
2013
2013
Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751
Objective ABT-751, a novel orally available antitubulin agent, is mainly eliminated as inactive glucuronide (ABT-751G) and… 
Review
2011
Review
2011
Antiangiogenic therapies in epithelial ovarian cancer.
BACKGROUND Angiogenesis is a critical component of tumor development and proliferation, and increased angiogenesis has been… 
2010
2010
Clinical outcome in children with recurrent neuroblastoma treated with ABT‐751 and effect of ABT‐751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro
ABT‐751, an orally bioavailable sulfonamide, binds β‐tubulin to inhibit microtubule polymerization. We described response and… 
Highly Cited
2008
Highly Cited
2008
STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells
Purpose: The aim of these studies was to characterize the action of STX140 in a P-glycoprotein–overexpressing tumor cell line… 
2007
2007
Evaluation of ABT-751 against childhood cancer models in vivo
SummaryObjectiveABT-751 is a novel antimitotic agent that binds tubulin at the colchicine binding site. ABT-751 is undergoing… 
2007
2007
Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth
PurposeABT-751 is an orally active antimitotic agent that is currently in Phase II clinical trials. This agent binds to the… 
Review
2007
Review
2007
Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia
Acute lymphocytic leukemia (ALL) is a heterogeneous group of disorders that are associated with a cure rate of > 80% in children… 
2005
2005
Phase 2 study of ABT-751 in patients with refractory metastatic colorectal carcinoma (CRC)
3537 Background: ABT-751, an oral antimitotic agent that binds to the colchicine site of β-tubulin and prevents microtubule… 
2004
2004
Phase I trial and pharmacokinetic (PK) study of ABT-751, an orally bioavailable tubulin binding agent, in pediatric patients with refractory solid tumors.
2080 Background: ABT-751 is an orally bioavailable sulfonamide that binds to the colchicine-binding site on β-tubulin and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)